Literature DB >> 15166396

Longitudinal risk of intracranial hemorrhage in patients with arteriovenous malformation of the brain within a defined population.

Alexander X Halim1, S Claiborne Johnston, Vineeta Singh, Charles E McCulloch, John P Bennett, Achal S Achrol, Stephen Sidney, William L Young.   

Abstract

BACKGROUND AND
PURPOSE: Accurate estimates for risk and rates of intracranial hemorrhage (ICH) in the natural course of patients harboring brain arteriovenous malformation (BAVM) are needed to provide a quantitative basis for planning clinical trials to evaluate interventional strategies and to help guide practice management.
METHODS: We identified patients with BAVM at the Kaiser Permanente Northern California health maintenance organization and documented their clinical course. The influences of age at diagnosis, gender, race-ethnicity, ICH at presentation, venous draining pattern, and BAVM size on ICH subsequent to presentation were studied using the multivariate Cox proportional hazards model and Kaplan-Meier curves.
RESULTS: We identified 790 patients with BAVM (51% female; 63% white; mean age+/-SD at diagnosis: 38+/-19 years) between 1961 and 2001. Patients who presented with ICH experienced a higher rate of subsequent ICH than those who presented without ICH under multivariate analysis (hazard ratio, 3.6; 95% CI, 1.1 to 11.9; P<0.032). The effect was similar across race-ethnicity and gender. This difference in ICH rates was greatest in the first year (7% versus 3% per year) and converged over time. The effect of subsequent ICH on functional status was similar to that of the initial ICH.
CONCLUSIONS: Presentation with ICH was the most important predictor of future ICH, confirming previous studies. Future ICH had similar impact on functional outcome as incident ICH. Intervention to prevent ICH would be of potentially greater benefit to patients presenting with ICH, although the advantage decreases over time.

Entities:  

Mesh:

Year:  2004        PMID: 15166396     DOI: 10.1161/01.STR.0000130988.44824.29

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  40 in total

1.  Apolipoprotein E epsilon 2 is associated with new hemorrhage risk in brain arteriovenous malformations.

Authors:  Ludmila Pawlikowska; K Y Trudy Poon; Achal S Achrol; Charles E McCulloch; Connie Ha; Kristen Lum; Jonathan G Zaroff; Nerissa U Ko; S Claiborne Johnston; Stephen Sidney; Douglas A Marchuk; Michael T Lawton; Pui-Yan Kwok; William L Young
Journal:  Neurosurgery       Date:  2006-05       Impact factor: 4.654

2.  Endovascular treatment accounts for a change in brain arteriovenous malformation natural history risk.

Authors:  X Lv; Z Wu; C Jiang; Y Li; X Yang; Y Zhang; M Lv; N Zhang
Journal:  Interv Neuroradiol       Date:  2010-07-19       Impact factor: 1.610

3.  Comparison of 2 approaches for determining the natural history risk of brain arteriovenous malformation rupture.

Authors:  Helen Kim; Charles E McCulloch; S Claiborne Johnston; Michael T Lawton; Stephen Sidney; William L Young
Journal:  Am J Epidemiol       Date:  2010-05-14       Impact factor: 4.897

4.  Management of brain arteriovenous malformations.

Authors:  Sherri A Braksick; Jennifer E Fugate
Journal:  Curr Treat Options Neurol       Date:  2015-07       Impact factor: 3.598

5.  Long-term outcomes in pediatric unruptured brain arteriovenous malformation treated by nonconservative management: a single center analysis.

Authors:  Sukwoo Hong; Hideki Ogiwara
Journal:  Childs Nerv Syst       Date:  2019-06-15       Impact factor: 1.475

6.  Acute management of brain arteriovenous malformations.

Authors:  Andreas Hartmann; J P Mohr
Journal:  Curr Treat Options Neurol       Date:  2015-05       Impact factor: 3.598

7.  Association of tumor necrosis factor-alpha-238G>A and apolipoprotein E2 polymorphisms with intracranial hemorrhage after brain arteriovenous malformation treatment.

Authors:  Achal S Achrol; Helen Kim; Ludmila Pawlikowska; K Y Trudy Poon; Charles E McCulloch; Nerissa U Ko; S Claiborne Johnston; Michael W McDermott; Jonathan G Zaroff; Michael T Lawton; Pui-Yan Kwok; William L Young
Journal:  Neurosurgery       Date:  2007-10       Impact factor: 4.654

8.  The rationale behind "A Randomized Trial of Unruptured Brain AVMs" (ARUBA).

Authors:  Christian Stapf
Journal:  Acta Neurochir Suppl       Date:  2010

Review 9.  Hemorrhage rates and risk factors in the natural history course of brain arteriovenous malformations.

Authors:  W Caleb Rutledge; Nerissa U Ko; Michael T Lawton; Helen Kim
Journal:  Transl Stroke Res       Date:  2014-06-15       Impact factor: 6.829

10.  Ten-year detection rate of brain arteriovenous malformations in a large, multiethnic, defined population.

Authors:  Rodney A Gabriel; Helen Kim; Stephen Sidney; Charles E McCulloch; Vineeta Singh; S Claiborne Johnston; Nerissa U Ko; Achal S Achrol; Jonathan G Zaroff; William L Young
Journal:  Stroke       Date:  2009-11-19       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.